Guidance on communication and informed consent with patients and their families for experimental individualized treatments

Communication with affected individuals and their guardians about experimental treatments is challenging, more so for individualized experimental treatment due to increased uncertainty. Here, we provide best practices for communicating with and obtaining consent from individuals and guardians for individualized antisense oligonucleotides based on the shared experiences of clinicians and ASO developers.